Expertise in
4
conditions

Xiao X. Wei

Sigmund Freud Str. 25, 
Bonn, NW, DE 
Expertise in
4
conditions
Sigmund Freud Str. 25, 
Bonn, NW, DE 

Overview

Xiao Wei practices practicing medicine in Bonn, Germany.

Ms. Wei is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, and Urothelial Cancer.

She is actively involved in clinical research, co-authoring 70 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Sigmund Freud Str. 25, Bonn, NW 53127, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Androgen deprivation therapy, Nivolumab, Docetaxel
Study Phase: Phase 2
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab
Study Phase: Phase 1
View 4 Less Clinical Trials

70 Total Publications

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: June 22, 2026

Frequently Asked Questions about Xiao X. Wei

Is Xiao X. Wei a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Xiao X. Wei is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xiao X. Wei participate in research or clinical trials?

Yes. Xiao X. Wei has published 70 articles and abstracts on conditions like Prostate Cancer. You can view a list of Xiao X. Wei's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Wei's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile